Preprint Article Version 1 This version is not peer-reviewed

Histology of the Primary Tumor, Lymph Node, and Tumor Size upon Neoadjuvant Treatment Predict Effectiveness of Complete Pathologic Response in Patients Undergoing Primary Lung Cancer Resections

Version 1 : Received: 11 July 2024 / Approved: 12 July 2024 / Online: 15 July 2024 (13:04:27 CEST)

How to cite: Damirov, F.; Stoleriu, M. G.; Manapov, F.; Boedeker, E.; Dreher, S.; Gerz, S.; Hehr, T.; Sandner, E.; Ott, G.; Hatz, R. A.; Preissler, G. Histology of the Primary Tumor, Lymph Node, and Tumor Size upon Neoadjuvant Treatment Predict Effectiveness of Complete Pathologic Response in Patients Undergoing Primary Lung Cancer Resections. Preprints 2024, 2024071084. https://doi.org/10.20944/preprints202407.1084.v1 Damirov, F.; Stoleriu, M. G.; Manapov, F.; Boedeker, E.; Dreher, S.; Gerz, S.; Hehr, T.; Sandner, E.; Ott, G.; Hatz, R. A.; Preissler, G. Histology of the Primary Tumor, Lymph Node, and Tumor Size upon Neoadjuvant Treatment Predict Effectiveness of Complete Pathologic Response in Patients Undergoing Primary Lung Cancer Resections. Preprints 2024, 2024071084. https://doi.org/10.20944/preprints202407.1084.v1

Abstract

Our study aimed to identify predictors for the effectiveness of tumor regression in lung cancer patients undergoing neoadjuvant treatment and cancer resections. Patients admitted between 2016 and 2022 were included in the study. Based on the histology of the tumor, patients were categorized into lung adenocarcinoma group (LUAD), and squamous cell carcinoma group (SQCA). Ninety-five patients with non-small cell lung cancer were included in the study. Fifty-eight (61.1%) and 37 (38.9%) patients were included in the LUAD and SQCA groups, respectively. Nine (9.5%), 56 (58.9%), and 30 (31.6%) patients were categorized with a tumor regression score of I, II, and III respectively. In multivariable analyses, histology of the primary tumor (SQCA), lymph node size in the preoperative CT scan (>1.7cm) and absolute tumor size reduction after neoadjuvant treatment (>2.6 cm) independently predict effectiveness of tumor regression (OR, [95% Confidence interval, p-value] of 6.88 [2.40-19.77, p70 years, extended resection >one lobe, and tumor recurrence or metastasis were identified as significant independent predictors of reduced overall survival. Assessment of tumor size before and after neoadjuvant treatment might help to identify high-risk patients with decreased survival and to improve patient management and care.

Keywords

lung cancer; PET/CT-scan; lymph node staging; neoadjuvant therapy; pathological response; tumor regression; overall survival

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.